Advandia Issues Shed Light On Bigger Problems In Drug Industry
Posted on Mar 31, 2010
As the public looks into the recent controversy over the potentially dangerous diabetes drug Advandia, it is becoming clear that there are large issues with the drug industry, the Food & Drug Administration (FDA), and the pharmaceutical industry. Most recently, A team at the Mayo Clinic collected evidence that most of the favorable commentaries linked to the drug Adandia came from voices that had significant ties to the drug industry while voices of dissent came from those who would not profit from speaking out for the drug.
About one-fourth of those with a favorable opinion of Advandia did not report their affiliation with the drug company that produces the product.
Advandia, also known as Rosiglitazone, is an insulin sensitizer that helps diabetics cope with their disease. Released in 2006, the drug, which is manufactured by GlaxoSmithKline, sees sales of over $1 billion worldwide. However, recent studies have found that the drug might be tied to a very increased risk of heart attack and other heart problems. While the FDA believes that these studies might be inconclusive, and while the drug company has conducted its own studies that show the correlation doesn’t exist, many have stopped taking the drug and started questioning the overall practices of the drug industry.
At this point in time, the FDA does not recommend that those taking Advandia stop taking their prescription, though those worried about the drug’s possible side effects should talk to their doctor and consider alternative treatments.